NCT04643977已完成不适用
An Open-Label Uncontrolled Single Center Study for the Evaluation of the Efficacy and Safety of the Dermal Filler "mARG-01-17" in the Facial Rejuvenation Therapy
Mesoestetic Pharma Group S.L.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年8月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The absolute change in Global Aesthetic Improvement Scale (GAIS)
研究概览
简要总结
The aim of the clinical investigation is to evaluate the performance of the mARG-01-17 dermal filler in the context of its efficacy and safety.
详细描述
The study is an open-label uncontrolled single-center study for the evaluation of the Performance (efficacy and safety) of the dermal filler "mARG-01-17" in the facial rejuvenation therapy. The design is of a not blinded, not randomized, single group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects;
- •Age between ≥35 and ≤65 years;
- •Subjects with WSRS (Wrinkle Severity Ranking Scale) score between 2 and 3;
- •Skin phototype I - VI;
- •Subjects with Glogau score between I and III;
- •Subjects with either chrono and photoaging wrinkles, wrinkles of expression (Line of expression); Dry and dehydrated skin;
- •Subjects who are willing to abstain from any cosmetic or surgical procedures (including botox injection) in the treatment area during the clinical investigation;
- •Clinically and anamnestically healthy individual, especially absence of diseases that could interfere with the cutaneous aging evaluation;
- •Absence of a history of significant hypersensitivity to food and drugs or known sensitivity to hyaluronic acid;
- •Subjects without significant body weight fluctuation;
- •Non-smoker and smokers;
- •Arterial blood pressure (BP) (after 5 min. at rest in the supine position) systolic 90 - 140 mmHg and diastolic 50 - 90 mmHg;
- •Heart rate (HR) (after 5 min. at rest in the supine position) over 50 beats/min and less than 90 beats/min;
- •Respiratory rate between 12 - 24 breaths/min;
- •Axillar body temperature of up to 370С;
- •Clinical-laboratory examinations within the reference ranges or with no clinically significant abnormalities;
- •Negative AIDS/HIV test;
- •Negative pregnancy test for the women with reproductive potential;
- •Reliable and acceptable method of contraception for the women of child-bearing potential;
- •Signed written Informed Consent Form.
排除标准
- •Subjects who had previously received permanent implants on the treated area;
- •Subjects who underwent facial surgery or were injected with dermal fillers in the facial area within the previous 6 months before enrollment;
- •Subjects who underwent facial procedures such as laser therapy, chemical peeling, dermo-abrasive treatments, or botulinum toxin injection within 12 months before enrollment;
- •Subjects who indicate signs of dermatological problems, such as cutaneous lesions, acne and/or other inflammatory diseases in active phase, hypertrophic scars or a tendency to keloid formation;
- •Subjects suffering from systemic diseases or alterations, such as diabetes mellitus, connective tissue diseases, uncontrolled systemic diseases;
- •Subjects, suffering from or who have history of immune system disorders, such as autoimmune diseases, HIV positive status, history of immune system degradation or recurrent herpes simplex or who are undergoing treatment with immunosuppressors or immunotherapy;
- •Subjects with known allergy or hypersensitivity to salicylic acid or its derivatives, any of the components of the product or cosmetic fillers to hyaluronic acid;
- •Pregnant women;
- •Breastfeeding women;
- •Absence of a reliable and effective method of contraception;
- •Subjects who are currently receiving another investigational treatment or who had participated in another clinical investigation within 30 days prior to study enrollment;
- •Subjects who suffer from another medical condition or who are receiving medication that in the Principal Investigator's judgment would prohibit inclusion in the study;
- •Subjects with limited mental activity and consistent comprehension ability; sportsmen and individuals on strenuous physical loading; prisoners;
- •Refusal to sign the Informed Consent Form.
结局指标
主要结局
The absolute change in Global Aesthetic Improvement Scale (GAIS)
时间窗: Between Day 0 to Day 90 (up to 12 weeks)
A 5-point scale rating global aesthetic improvement in appearance, compared to pre-treatment, as judged by the Principal Investigator. Grade 1 - Exceptional improvement, grade 5 - Worsened.
Safety endpoint
时间窗: Between Day 0 to Day 90
The frequency and severity of adverse events (AEs)
次要结局
- The change in Wrinkle Severity Ranking Scale (WSRS)(Between Day 0 and Days 15, 30, 45, 60 and 90 (up to 2, 4, 6, 8 and 12 weeks respectively))
- Subject satisfaction(Days 15, 30, 45, 60 and 90 (up to 2, 4, 6, 8 and 12 weeks respectively))
- The absolute change in Global Aesthetic Improvement Scale (GAIS)(Between Day 0 and Days 15, 30, 45, 60 (up to 2, 4, 6 and 8 weeks respectively))
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Safety and Performance of PTMC Dermal FillerModerate to Severe Nasolabial FoldNCT06316479Aqpha Medical B.V.120
招募中
早期 1 期
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLCNon Small Cell Lung CancerNCT05060796Second Affiliated Hospital of Guangzhou Medical University11
已完成
不适用
Clinical Investigation on the Performance and Safety of DermoRelizema EcofoamDermatitisNCT04826471Relife S.r.l.40
终止
3 期
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.AnemiaNCT00462384Hoffmann-La Roche39
已完成
不适用
A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty SkinKeratosis, ActinicActinic LesionSolar Keratosis/SunburnHyperkeratosisHyperkeratotic CallusHyperkeratotic Actinic KeratosisLesion HyperkeratoticNCT05356572Mirka Ltd26